Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio, discussed EPI-321, an investigational treatment for facioscapulohumeral muscular dystrophy.
Alexandra Collin de l’Hortet, PhD
Advertisement
Articles by Alexandra Collin de l’Hortet, PhD
The head of therapeutics at Epic Bio discussed EPI-321, an investigational treatment for facioscapulohumeral muscular dystrophy.
Advertisement
